Semaglutide and cardiovascular outcomes in obesity without diabetes

Semaglutide and cardiovascular outcomes in obesity without diabetes

New England Journal of Medicine

2023

Study summary

SELECT evaluated semaglutide for cardiovascular event reduction in adults with overweight or obesity without diabetes.

Peptides studied

Stack studied

Metabolic Stack

Key findings

Semaglutide reduced major adverse cardiovascular events in this population.

Study details

Study type

randomized clinical trial

Journal

New England Journal of Medicine

DOI / PubMed

10.1056/NEJMoa2307563

Year

2023

Explore peptide profiles

Discover compounds, understand their mechanisms, and explore the research behind each peptide.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.